Table 1 Clinical and biochemical characteristics of heFH and control probands
From: Current causes of death in familial hypercholesterolemia
heFH Cases | Controls | P | |
|---|---|---|---|
N | 83 | 83 | |
Age (years) | 54.3 (10.7) | 54.5 (10.5) | 0.884 |
Women, N (%) | 45 (54.2) | 44 (53.0) | 0.876 |
Current smokers, N (%) | 11 (13.3) | 22 (26.5) | 0.098 |
BMI (Kg/m2)a | 25.8 (3.94) | 26.3 (4.17) | 0.479 |
Systolic blood pressure (mmHg) | 123.1 (12.7) | 123.3 (14.0) | 0.956 |
Diastolic blood pressure (mmHg) | 74.6 (8.97) | 75.3 (9.97) | 0.628 |
Hypertension, N (%) | 24 (28.9) | 16 (19.8) | 0.172 |
Type 2 diabetes mellitus, N (%) | 7 (8.4) | 7 (8.4) | 1.000 |
Cardiovascular disease, N (%) | 7 (8.4) | 2 (2.4) | 0.087 |
Total cholesterol (mg/dL) | 363 (412–306) | 220 (198–252) | < 0.001 |
LDL cholesterol (mg/dL)b | 283 (222–339) | 130 (105–154) | < 0.001 |
HDL cholesterol (mg/dL)c | 56.2 (13.4) | 62.0 (24.2) | 0.079 |
Triglycerides (mg/dL) | 114 (52.3) | 141 (154) | 0.209 |
Glucose (mg/dL) | 89.5 (18.8) | 91.3 (20.1) | 0.626 |
Statin treatment, N (%) | 83 (100) | 19 (22.9) | < 0.001 |
Onset age of statin treatment (years) | 32.8 (9.43) | 51.3 (8.84) | < 0.001 |